Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

MMWR Recomm Rep. 1996 Dec 27;45(RR-15):1-30.

Abstract

This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous recommendations for use of immune globulin (IG) for protection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1-5). For preexposure protection, hepatitis A vaccine can now be used instead of IG in many circumstances; for postexposure prophylaxis, the recommendations for IG use are unchanged.

Publication types

  • Guideline
  • Practice Guideline

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Disease Outbreaks
  • Female
  • Hepatitis A / diagnosis
  • Hepatitis A / epidemiology
  • Hepatitis A / prevention & control*
  • Hepatitis A / transmission
  • Hepatitis A Vaccines
  • Hepatitis A Virus, Human / immunology*
  • Humans
  • Immunization, Passive / standards*
  • Immunoglobulins / administration & dosage*
  • Male
  • Middle Aged
  • Population Surveillance
  • Risk Factors
  • Seroepidemiologic Studies
  • United States / epidemiology
  • Vaccination / standards*
  • Vaccines, Inactivated / administration & dosage*
  • Vaccines, Inactivated / immunology
  • Viral Hepatitis Vaccines / administration & dosage*
  • Viral Hepatitis Vaccines / immunology

Substances

  • Hepatitis A Vaccines
  • Immunoglobulins
  • Vaccines, Inactivated
  • Viral Hepatitis Vaccines